Skip to search formSkip to main contentSkip to account menu

orteronel

Known as: Androgen Synthesis Inhibitor TAK-700, 6-((7S)-7-hydroxy-6,7-dihydro-5h-pyrrolo(1,2-c)imidazol-7-yl)-N-methyl-2-naphthalenecarboxamide, 6-((7S)-7-hydroxy-6,7-dihydro-5H-pyrrolo(1,2-c)imidazol-7-yl)-N-methyl-2-naphthamide 
An orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrogen activity… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

ImidazolesNaphthalenes
NCIt Antineoplastic Agent Terminology

Narrower (1)

TAK-700

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight…
Various novel androgen receptor (AR) targeting drugs have been developed recently and have shown beneficial effects on survival… 
2015
2015
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer
SummaryBackground: Docetaxel–prednisone (DP) is an approved therapy for metastatic castration-resistant prostate cancer (mCRPC… 
Review
2014
Review
2014
The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor
Prostate cancer treatment has evolvedthrough the varying eras of therapy fromone of predominantly hormonal agentswithout much… 
2014
2014
Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen
Purpose: Orteronel (TAK-700) is an investigational, nonsteroidal, oral, inhibitor of androgen synthesis with greater specificity… 
2014
2014
Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial)
5008 Background: Orteronel, an investigational, non-steroidal, selective 17,20-lyase inhibitor, demonstrated improved… 
Review
2013
Review
2013
Targeting the Adrenal Gland in Castration-Resistant Prostate Cancer: A Case for Orteronel, a Selective CYP-17 17,20-Lyase Inhibitor
Androgen and the androgen receptor (AR) pathway remain the key targets for emerging new therapies against castration-resistant… 
Review
2013
Review
2013
Optimal Pharmacotherapeutic Management of Hormone-Sensitive Metastatic Prostate Cancer
The mainstay of initial therapy of metastatic prostate cancer has not changed since 1941 when Huggins and Hodges described the… 
2013
2013
A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant…
59 Background: Orteronel is an investigational non-steroidal, selective inhibitor of 17,20-lyase, a key enzyme in the production… 
2013
2013
Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer
Androgen deprivation therapy (ADT) with medical or surgical castration is the mainstay of therapy in men with metastatic prostate… 
2013
2013
Differential effects of galeterone, abiraterone, orteronel, and ketoconazole on CYP17 and steroidogenesis.
184 Background: Because CYP17 has a central role in converting progestogens to androgens, inhibitors have been developed to treat… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)